Mylan Signs Deal With Gilead To Enhance Access To TAF-based HIV Treatments

(RTTNews) - Mylan Inc. (MYL) announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences Inc. (GILD) under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide or TAF as both a single agent product and in combination with other drugs. Tenofovir Alafenamide or TAF is an investigational antiretroviral drug for the treatment of HIV-1 infection.

The license being granted to Mylan extends to 112 countries, which together account for more than 30 million people living with HIV, representing 84% of those infected globally.

As part of the licensing deal, on U.S. Food and Drug Administration (FDA) approval, Mylan will receive a technology transfer from Gilead, enabling the company to manufacture low-cost versions of Tenofovir Alafenamide (TAF), if approved as a single agent or in approved combinations containing Tenofovir Alafenamide (TAF) for developing markets.